Lumos Pharma, Inc. LUMO
Set alert
4.34 +4.34 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 37.54M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -2.01
- Beta
- 0.33
- Short ratio
- 0.59
- Inst. own
- 24.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 7, 2024
- 50-d avg
- 4.23
- 200-d avg
- 3.10
- 1y target
- 4.25
Analyst view
Consensus: buy
Buy
Price target (mean) 4.25
Ratings (0m) 2 1 buy · 1 hold · 0 sell
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 3
- 2 months ago 3
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.56 | -0.65 – -0.47 | -1.17 | +52.1% | 6.93M | +739.4% | 2 |
| Next quarter | -0.47 | -0.47 – -0.47 | -1.29 | +63.6% | 150.00K | -9.1% | 1 |
| Current year | -3.32 | -3.36 – -3.27 | -4.18 | +20.7% | 7.78M | +279.5% | 2 |
| Next year | -1.96 | -2.41 – -1.50 | -3.32 | +41.0% | 1.10M | -85.9% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Oct 24, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Oct 23, 2024 | Jones Trading | Downgrade | Buy | Hold |
| Sep 27, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 24, 2024 | EF Hutton | Initiated | — | Buy |
| Aug 2, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 8, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 11, 2023 | Oppenheimer | Maintained | Outperform | Outperform |
| Dec 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 6, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 22, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 15, 2023 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 10, 2023 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 10, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 24, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jun 22, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 4, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 6, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Dec 8, 2022 | Jefferies | Downgrade | Buy | Hold |
| Nov 15, 2022 | Jefferies | Downgrade | Buy | Hold |
| Jul 20, 2022 | Oppenheimer | Initiated | — | Outperform |
| Nov 4, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Jul 21, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 11, 2021 | Stifel | Upgrade | Hold | Buy |
| Dec 3, 2020 | Cantor Fitzgerald | Initiated | — | Overweight |
| Nov 23, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 26, 2020 | Piper Sandler | Initiated | — | Overweight |
| Aug 4, 2020 | HC Wainwright & Co. | Initiated | — | Buy |